Aravive
3730 Kirby Drive
Suite 1200
Houston
TX
77098
United States
Tel: (936) 355-1910
Website: https://aravive.com/
95 articles about Aravive
-
Aravive Reports Third Quarter 2021 Financial Results and Provides Corporate Updates
10/28/2021
Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative, targeted therapeutics to treat life-threatening cancers, today announced recent corporate updates and financial results for the third quarter ended September 30, 2021.
-
Aravive to Present New Preliminary Data from Phase 1b Trial Evaluating AVB-500 in Clear Cell Renal Cell Carcinoma at 2021 Society for Immunotherapy of Cancer Annual Meeting
10/1/2021
Aravive, Inc. (Nasdaq: ARAV), today announced that new preliminary safety, pharmacokinetic, pharmacodynamic, and clinical activity data from the Phase 1b portion of its open-label Phase 1b/2 trial evaluating AVB-500 in combination with cabozantinib in patients with clear cell renal cell carcinoma (ccRCC) will be presented at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting.
-
Aravive to Participate in Fireside Chat at Cantor Fitzgerald Virtual Global Healthcare Conference
9/16/2021
Aravive, Inc., a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive, and Reshma Rangwala, M.D., Ph.D., Chief Medical Officer of Aravive, will participate in a virtual fireside chat at the Cantor Fitzgerald Virtual Global Healthcare Conference on September 30, 2021 at 9:20 AM ET.
-
Aravive to Participate in Fireside Chat at H.C. Wainwright 23rd Annual Global Investment Conference
9/1/2021
Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive, and Reshma Rangwala, M.D., Ph.D., Chief Medical Officer of Aravive, will participate in a virtual fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021.
-
Aravive Reports Second Quarter 2021 Financial Results and Provides Corporate Updates
8/5/2021
Aravive, Inc., a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, announced recent corporate updates and financial results for the second quarter ended June 30, 2021.
-
Aravive to Participate in Fireside Chat at 2021 BTIG Biotechnology Conference
7/27/2021
Aravive, Inc., a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive, and Reshma Rangwala, M.D., Ph.D., Chief Medical Officer of Aravive, will participate in a virtual fireside chat at the 2021 BTIG Biotechnology Conference on August 9, 2021, at 9:30 AM ET.
-
Aravive Achieves Second Development Milestone from 3D Medicines
7/15/2021
Aravive Inc., a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, announced that it achieved a $3 million development milestone payment from its licensee, 3D Medicines Inc.
-
Aravive to Participate in Fireside Chat at 2021 William Blair Biotech Focus Conference
7/7/2021
Aravive, Inc., a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, announced that Gail McIntyre, Ph.D., DBAT, Chief Executive Officer of Aravive, and Reshma Rangwala, M.D., Ph.D., Chief Medical Officer of Aravive, will participate in a virtual fireside chat at the 2021 William Blair Biotech Focus Conference on July 15, 2021, at 3:00 PM ET.
-
Aravive Announces Positive Initial Results from Phase 1b Portion of the Phase1b/2 Study of AVB-500 in Combination with Cabozantinib in Clear Cell Renal Carcinoma
6/24/2021
Encouraging Pharmacokinetics, Pharmacodynamics and Safety Profile at 15mg/kg of AVB-500
-
BioSpace Movers & Shakers, May 21
5/21/2021
Biopharma and life sciences companies strengthen their leadership teams and board with these Movers & Shakers. -
Aravive Announces Three New Appointments to its Board of DirectorsFurther Strengthens Senior Executive Leadership Team
5/18/2021
Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced the appointments of John A. Hohneker, M.D., Sigurd C. Kirk, and Peter T.C. Ho, M.D., Ph.D. to its Board of Directors. Mr. Kirk was also appointed to serve on the Audit Committee of the Board.
-
Aravive Reports First Quarter 2021 Financial Results and Announces Plans to Investigate AVB-500 in Clinical Trial as First-Line Treatment for Pancreatic Cancer
5/6/2021
Aravive continues to expand development of AVB-500 in multiple indications and combination treatments with first-line treatment for pancreatic cancer
-
Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant Ovarian Cancer
4/27/2021
Aravive Inc., a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, announced the Company has dosed the first patient in its Phase 3 trial of AVB-500 in platinum resistant ovarian cancer.
-
Aravive Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Updates
3/16/2021
Aravive, Inc., a clinical-stage oncology company developing transformative therapeutics, announced recent corporate updates and financial results for the fourth quarter and full year ended December 31, 2020.
-
Clinical Catch-Up: March 8-12
3/15/2021
It was another busy week for clinical trial announcements. Here’s a look including trials for COVID-19, migraine, Parkinson's disease, Alzheimer's, HIV and more. -
Aravive to Present Phase 1b Data Evaluating AVB-500 in Platinum Resistant Ovarian Cancer at 2021 Society of Gynecologic Oncology Annual Meeting
3/12/2021
- Aravive, Inc. (Nasdaq:ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that updated data from its Phase 1b trial evaluating AVB-500 in platinum resistant ovarian cancer (PROC) will be presented at the 2021 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer. Additionally, a trial in progress poster will be presented on an open label Phase 1/2 investigator-sponsored trial of AVB-500
-
Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 in Patients with Clear Cell Renal Cell CarcinomaLead Compound AVB-500 Now Being Evaluated in Broad Range of Cancers
3/8/2021
Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that the Company has dosed its first patient in an open label Phase 1b/2 clinical trial to evaluate the safety, pharmacokinetic, and preliminary clinical activity of AVB-500, including progression free survival. The trial will enroll patients with advanced clear cell renal cell carcinoma (ccRCC) that have progressed on front-line tr
-
Aravive to Participate in Upcoming Virtual Investor Conferences in March 2021
3/2/2021
Aravive, Inc., a clinical-stage oncology company developing transformative therapeutics, announced that the Company will present and conduct one-on-one meetings at the following two virtual investor conferences in March 2021
-
Aravive Announces $21.0 Million Registered Direct Offering with Eshelman Ventures, LLC Priced At-The-Market
2/16/2021
Aravive, Inc., a clinical-stage oncology company developing transformative therapeutics, announced that it has entered into a securities purchase agreement with Eshelman Ventures, LLC to sell 2,875,000 shares of common stock at a price of $7.29 per share in a registered direct offering.
-
Aravive to Present at the H.C. Wainwright Virtual BioConnect Conference
1/4/2021
Aravive, Inc., a clinical-stage oncology company developing transformative therapeutics, announced the Company will present at the H.C. Wainwright Virtual BioConnect Conference taking place January 11-14, 2021.